Jump to main content Jump to site nav

For medical information relating to Covid-19, please consult the World Health Organisation or local healthcare provision.

Actinomycin D

Molecular FormulaC₆₂H₈₆N₁₂O₁₆
Average mass1255.417 Da
Monoisotopic mass1254.628418 Da
ChemSpider ID10482167

- 10 of 10 defined stereocentres

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

Actinomycin D [JP15]

1CC1JFE158

200-063-6 [EINECS]

2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide

2-Amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phe

2-amino-4,6-diméthyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-triméthyl-6,13-bis(1-méthyléthyl)-1,4,7,11,14-pentaoxohexadécahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatétraazacyclohexadécin-10-yl]-3H-phé

2-Amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazin-1,9-dicarboxamid

2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide

2-Amino-N,N'-bis[(6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3H-phenoxazin -1,9-dicarboxamid [German] [ACD/IUPAC Name]

More...

2-Amino-N,N'-bis[(6S,9R,10S,13R,18aS)-6,13-diisopropyl-2,5,9-triméthyl-1,4,7,11,14-pentaoxohexadécahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatétraazacyclohexadécin-10-yl]-4,6-diméthyl-3-oxo-3H-phénoxazin e-1,9-dicarboxamide [French] [ACD/IUPAC Name]

3H-phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-

3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N¹,N⁹-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohe xadecin-10-yl]-4,6-dimethyl-3-oxo- [ACD/Index Name]

3H-phenoxazine-1,9-dicarboxamide, 2-amino-N1,N9-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-

50-76-0 [RN]

Actinomycin AIV

actinomycin C1

Actinomycin I1

actinomycin IV

Actinomycin X1

Acto-D

AU1575000

Chounghwamycin B

dactinomicina [Spanish] [INN]

dactinomycin [INN] [USP] [Wiki]

dactinomycine [French] [INN]

dactinomycinum [Latin] [INN]

Dilactone actinomycin D acid

MERACTINOMYCIN

MFCD00005033 [MDL number]

noxazin-1,9-dicarboxamid

noxazine-1,9-dicarboxamide

Oncostatin K

дактиномицин [Russian] [INN]

داكتينوميسين [Arabic] [INN]

放线菌素D [Chinese] [INN]

1402-38-6 [RN]

1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-p

232-485-1 [EINECS]

2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamide

2-amino-4,6-dimethyl-3-oxo-N,N'-bis(7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-dipropan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadec-6-yl)phenoxazine-1,9-dicarboxamide

2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide

2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

2-amino-N,N'-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide

2-amino-N,N'-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxophenoxazine-1,9-dicarboxamide

2-amino-N,N'-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide

4173766 [Beilstein]

8052-16-2 [RN]

Actactinomycin A IV

ActD

ACTINOMYCIN

Actinomycin D, Streptomyces sp. - CAS 50-76-0 - Calbiochem

Actinomycin- IV

ActinomycinD

Cactinomycin

CHEBI:27666

COSMEGEN

Dactinomicina

Dactinomycin, RNA Polymerase I Inhibitor I, Pol I Inhibitor I

Dactinomycine

Dactinomycinum

DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA

GNF-PF-1977

henoxazine-1,9-dicarboxamide

Lyovac cosmegen

Lyovac Cosmegen (trade name)

N1,N9-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phe

NCGC00161622-01

UNII:1CC1JFE158

UNII-0OCC969V50

UNII-1CC1JFE158

UPCMLD-DP055:002

Less...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1155 [DBID]

605235 [DBID]

HBF 386 [DBID]

HSDB 3220 [DBID]

NCI-C04682 [DBID]

01815_FLUKA [DBID]

A1410_SIGMA [DBID]

A4262_SIGMA [DBID]

A9415_SIGMA [DBID]

AI3-26374 [DBID]

More...

Experimental data
Predicted - ACD/Labs
Predicted - ChemAxon
Predicted - Mcule

Experimental Physico-chemical Properties
- Experimental Melting Point:
  
  251-253 °C Sigma-Aldrich SIGMA-01815
Miscellaneous
- Therapeutical Effect:
  
  Protein Synthesis Inhibitors,Nucleic Acid Synthesis Inhibitors Sean Ekins

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

Density:	1.4±0.1 g/cm³
Boiling Point:	1386.0±65.0 °C at 760 mmHg
Vapour Pressure:	0.0±0.3 mmHg at 25°C
Enthalpy of Vaporization:	211.5±3.0 kJ/mol
Flash Point:	792.1±34.3 °C
Index of Refraction:	1.656
Molar Refractivity:	323.7±0.5 cm³
#H bond acceptors:	28
#H bond donors:	6
#Freely Rotating Bonds:	8
#Rule of 5 Violations:	3

ACD/LogP:	-4.03
ACD/LogD (pH 5.5):	-2.38
ACD/BCF (pH 5.5):	1.00
ACD/KOC (pH 5.5):	1.21
ACD/LogD (pH 7.4):	-2.39
ACD/BCF (pH 7.4):	1.00
ACD/KOC (pH 7.4):	1.18
Polar Surface Area:	356 Å²
Polarizability:	128.3±0.5 10^-24cm³
Surface Tension:	53.9±7.0 dyne/cm
Molar Volume:	880.7±7.0 cm³

Click to predict properties on the Chemicalize site

Patents	Personal Collections
Publication or Magazine Article	Web-based Article (blog or commentary)
Available Chemicals Databases	Biological Properties
Chemical Reactions	Chemical Safety Data
Drugs or Compounds in Development	Imaging Agents
Information Aggregators	Journal Publishers via MeSH
Ligand/binding/crystal Structure Databases	Metabolic Pathways
Molecular Libraries Screening Center Network	Natural Products
NIH Substance Repository	Physical Properties (including SAR/QSAR databases)
Protein 3D Structures	Spectroscopy Databases
Substance Vendors	Theoretical Properties
Toxicology/Environmental Databases	Virtual Library

Actinomycin D

More details:

Experimental Melting Point:

Therapeutical Effect:

Search ChemSpider:

Search Google: